6:07 PM
 | 
May 20, 2008
 |  BC Extra  |  Clinical News

Tioga's asimadoline misses Phase IIb endpoint

Tioga (San Diego, Calif.) said all three doses of asimadoline missed the primary endpoint of a significant improvement vs. placebo in the percent of months a patient was a responder for adequate relief of pain in a Phase IIb trial to treat irritable bowel syndrome (IBS). The double-blind, U.S. trial...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >